Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04886050 · ClinicalTrials.gov registry record · Phase 1

Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

A Phase 1 study, sponsored by LG Chem.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT04886050 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 23 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04886050, a Phase 1 study, has completed, sponsored by LG Chem.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

This is an open-label, randomized, crossover, single dose study. Two single doses of LC350189(tablet or capsule formulations) will be administered with a washout period of at least 4-day between the doses to investigate the relative bioavailability of LC350189 after administration via tablet formulation compared with capsule formulation and to evaluate basic systemic pharmacokinetic parameters of the tablet formulation compared to the capsule formulation of LC350189.

Interventions

  • DRUG LC350189 Tablet
  • DRUG LC350189 Capsule

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2021-07-31
Est. Completion 2021-12-10
Phase Phase 1

Sponsor

LG Chem

13 total trials

What the Registry Record Tells You About NCT04886050

The ClinicalTrials.gov registry entry for NCT04886050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which LC350189 Tablet is the first listed.

NCT04886050 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04886050 about?

NCT04886050 is a clinical study titled "Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults". This is an open-label, randomized, crossover, single dose study. Two single doses of LC350189(tablet or capsule formulations) will be administered with a washout period of at least 4-day between the doses to investigate the relative bioavailability of LC350189 after administration via tablet formula...

What is the current status of trial NCT04886050?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2021-07-31. Estimated completion is 2021-12-10.

What interventions are being tested in trial NCT04886050?

The interventions under investigation include: LC350189 Tablet (DRUG), LC350189 Capsule (DRUG).

Who is sponsoring clinical trial NCT04886050?

This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.